Compare Incyte Corporation (INCY) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Incyte Corporation trades at $120.85 (market cap $24.54B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.85. The key difference: Incyte Corporation is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| INCY | TMF | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $44.14 |
52-Week Low | $81.61 | $30.59 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.93 with a 0.95% daily gain. Technical indicators show a bearish trend with moving averages and ADX signaling sell conditions, while oscillators remain neutral. The ETF faces significant fundamental challenges with unavailable valuation and profitability metrics, reflecting its leveraged structure that amplifies both gains and losses in long-duration treasuries.
The outlook for TMF remains high-risk due to its daily leverage reset mechanism, making it unsuitable for long-term holdings. While some analysts see potential at bond market lows, the dominant view cautions against current purchases given the substantial erosion of value over time, with $10,000 invested five years ago now worth approximately $1,527 according to 24/7 Wall Street analysis from June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
